Vertex Pharmaceuticals Incorporated Financials

Market Capitalization $117.36 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	32.82
Forward PE	24.35
Price to Sales TTM	$10.57
Price to Book MRQ	$7.12
Enterprise to Revenue	9.89
Enterprise to EBITDA	23.95

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-8.91%
Operating Margin	37.22%
Return on Assets TTM	11.77%
Return on Equity TTM	-5.64%

Income Statement

Revenue TTM	$11,099,700,224
Revenue per Share TTM	$43.09
Quarterly Revenue Growth	3.00%
Gross Profit TTM	$5,892,899,840
EBITDA	$4,877,300,000
Net Income to Common TTM	$-988,899,968
Diluted EPS TTM	$-3.80
Quarterly Earnings Growth YoY	-41.20%

Balance Sheet

Total Cash MRQ	$6,201,200,128
Total Cash per Share MRQ	$24.15
Total Debt MRQ	$
Total Debt to Equity MRQ	10.00
Current Ratio MRQ	2.65
Book Value per Share MRQ	$64.20

Cash Flow

Operating Cash Flow TTM	$-980,300,032
Levered Free Cash Flow TTM	$2,634,387,456

VRTX Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	256,940,382
Float Shares	256,055,043
Avg 10 Volume	1,466,618
Avg 30 Volume	None
Shares Short	4,034,849
Short Ratio	2.78
Short % of Shares	1.77%
% Held by Insiders	0.15%
% Held by Institutions	97.64%

Stock Price Summary

Beta	0.42
Fifty Two Week Low	$377.85
Fifty Two Week High	$519.88
Fifty Two Week Change	-3.25%
Day 50 MA	$454.73
Day 200 MA	$463.89

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2000-08-24